Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment

Authors: Mehmet Soy 1, Gökhan Keser 2, Pamir Atagündüz 3, Fehmi Tabak 4, Işık Atagündüz 5, Servet Kayhan COVID-19 infection has a heterogenous disease course; it may be asymptomatic or causes only mild symptoms in the majority of the cases,…[...]

Read More

Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults

Authors: Romina Libster, M.D., Gonzalo Pérez Marc, M.D., Diego Wappner, M.D., Silvina Coviello, M.S., Alejandra Bianchi, Virginia Braem, Ignacio Esteban, M.D., Mauricio T. Caballero, M.D., Cristian Wood, M.D., Mabel Berrueta, M.D., Aníbal Rondan, M.D., Gabriela Lescano, M.D., et al., for the Fundación INFANT–COVID-19…[...]

Read More

Considerations for Certain Concomitant Medications in Patients With COVID-19

Authors: NIH Patients with COVID-19 who are receiving concomitant medications (e.g., angiotensin-converting enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs], statins, systemic or inhaled corticosteroids, nonsteroidal anti-inflammatory drugs, acid-suppressive therapy) for…[...]

Read More